BioSpace News Archive

Alnylam Pharmaceuticals, Inc. said that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association.

Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.

NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova branded products by Sonoma in the European Union.

Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Woodward Pharma Services LLC, has just commercialized its Supplemental Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for a generic version of Sodium Acetate Injection 4 mEq/mL marketed by Fresenius Kabi USA LLC.

Extreme weather conditions and power outages are especially common in the winter season. Continue reading to learn more about how to keep your food safe during an emergency.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11.

Tonix Pharmaceuticals Holding Corp. today announced the presentation of additional safety and tolerability data from RESILIENT, the second positive Phase 3 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at Biotech Showcase™ 2024 in San Francisco, January 8-10.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th.

Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate being developed to treat complications of extremely premature birth.